Characteristic | Overall, n(%) | Groups | p-value | |
---|---|---|---|---|
TOR | TAM | |||
Age | Â | Â | Â | 0.053 |
  < 40 | 12(13.0) | 3 | 9 |  |
  ≥ 40 | 80(87.0) | 44 | 36 |  |
BMI | Â | Â | Â | 0.880 |
  < 24 | 73(79.3) | 37 | 36 |  |
  ≥ 24 | 19(20.7) | 10 | 9 |  |
Surgery | Â | Â | Â | 0.273 |
 Mastectomy | 54(58.7) | 25 | 29 |  |
 BCS | 38(41.3) | 22 | 16 |  |
Pathology | Â | Â | Â | 0.890 |
 IDC | 72(78.3) | 37 | 35 |  |
 DCIS | 7(7.6) | 4 | 3 |  |
 Others | 13(14.1) | 6 | 7 |  |
Tumors | Â | Â | Â | 0.717 |
  ≤ 2.0 cm | 67(72.8) | 35 | 32 |  |
  > 2.0 cm | 25(27.2) | 12 | 13 |  |
Nodes status | Â | Â | Â | 0.830 |
 Negative | 79(85.9) | 40 | 39 |  |
 Positive | 13(14.1) | 7 | 6 |  |
Grade | Â | Â | Â | 0.655 |
 I | 15(16.3) | 9 | 6 |  |
 II | 47(51.1) | 25 | 22 |  |
 III | 11(12.0) | 4 | 7 |  |
 NA | 19(20.7) | 9 | 10 |  |
ER | Â | Â | Â | 0.430 |
  ≥ 50% | 86(93.5) | 43 | 43 |  |
  < 50% | 6(6.5) | 4 | 2 |  |
PR | Â | Â | Â | 0.399 |
  ≥ 20% | 69(75) | 37 | 32 |  |
  < 20% | 23(25) | 10 | 13 |  |
HER-2 | Â | Â | Â | 0.430 |
 positive | 6(6.5) | 4 | 2 |  |
 negative | 86(93.5) | 43 | 43 |  |
Subtype | Â | Â | Â | 0.164 |
 Luminal A like | 40(43.5) | 24 | 16 |  |
 Luminal B HER2 negative | 46(50.0) | 19 | 27 |  |
 Luminal B HER2 positive | 6(6.5) | 4 | 2 |  |
Ki67 | Â | Â | Â | 0.554 |
  < 14% | 58(63.0) | 31 | 27 |  |
  ≥ 14% | 34(37.0) | 16 | 18 |  |
Chemotherapy | Â | Â | Â | 0.709 |
 Yes | 33(35.9) | 16 | 17 |  |
 No | 59(64.1) | 31 | 28 |  |
Radiotherapy | Â | Â | Â | 0.828 |
 Yes | 44(47.8) | 23 | 21 |  |
 No | 48(52.2) | 24 | 24 |  |
Trastuzumab | Â | Â | Â | 0.328 |
 Yes | 4(4.3) | 3 | 1 |  |
 No | 88(95.7) | 44 | 44 |  |